Prospera Financial Services Inc Zentalis Pharmaceuticals, Inc. Transaction History

Prospera Financial Services Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.09 - $16.13 $124,655 - $491,610	30,478 Added 166.53%	48,780 $199,000
Q1 2024 Aug 13, 2024	SELL	$10.83 - $16.49 $267,988 - $408,045	-24,745 Reduced 50.73%	24,035 $378,000
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $180,091 - $368,419	18,302 New	18,302 $277,000
Q2 2022 Aug 08, 2022	SELL	$17.91 - $52.25 $38,703 - $112,912	-2,161 Reduced 96.04%	89 $2,000
Q1 2022 May 04, 2022	BUY	$41.58 - $80.89 $93,555 - $182,002	2,250 New	2,250 $104,000

143

68M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $129M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

Stay updated on Prospera Financial Services Inc with notifications on news.